Navigation Links
Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia

nderlying genetic causes of disease rather than just the physical symptoms. Santaris Pharma holds the world wide patent rights to the exploitation of LNA in pharmaceuticals and presently has three drugs in preclinical or clinical development. The lead drug candidate, SPC2996, is currently undergoing international, multicenter, phase I/II clinical studies in Chronic Lymphocytic Leukemia (CLL).

For further company information see www.santaris.com

Detailed results of the Phase I/II Study

A PDF of the results presented at the American Society of Clinical Oncology (ASCO) in poster format can be viewed and/or downloaded from the News section of the Company's website, www.santaris.com.

The Clinical Trial reported here was an open-label, international, multi-centre, dose-escalating study in 25 patients with relapsed or refractory Chronic Lymphocytic Leukaemia, requiring treatment. Twelve expert haematology-oncology specialists participated, including:

* Prof Bertrand Coiffier, Centre Hospitalier, Lyon-Sud, France (International Coordinating Investigator);

* Prof Hervé Tilly, Centre Henri Becquerel, Rouen, France (ASCO Presenter);

* Dr Bruno Cazin, Hopital Huriez, Lille, France;

* Prof Mauricette Michallet, Hoptial Edourd Heriot, Lyon, France;

* Prof John Radford, Christie Hospital NHS Trust, Manchester, UK (Prinicipal Investigator, UK);

* Dr Claire Dearden, The Royal Marsden NHS Foundation Trust, Surrey, UK;

* Prof Peter Hillman, Leeds General Infirmary, Leeds, UK;

* Prof Martin Dyer, MRC Toxicology Unit, Leicester, UK;

* Dr Christian Geisler, Rigshopitalet, Copenhagen, Denmark (Principal Investigator, Denmark);

* Dr Ole Gadeber, Vejle Sygehus, Vejle, Denmark;

* Dr Annemarie Dalseg, KAS Herlev, Herlev, Denmark;

* Dr Brian Link, Holden Comprehensiv
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation ... release its second quarter 2015 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, August ... quarter and other business developments. Interested parties ...
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)...  Today we bring you a special edition of #MedicareMonday on Medicare,s 50 th ... of our Medicare resources and continue highlighting the success of the prescription drug benefit, ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
(Date:8/1/2015)... ... August 01, 2015 , ... Professional ... portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 ... state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional ...
(Date:8/1/2015)... ... 01, 2015 , ... “ reTXT ” was featured on NewsWatch as part ... on the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch ... clarify, edit and delete any message including ones already sent. , While text messaging ...
(Date:7/31/2015)... ... 2015 , ... When the weather turned hot and warm-season turfgrasses, such as ... called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names ... new type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure ...
(Date:7/31/2015)... ... 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle ... provider of Exilis non-surgical fat reduction in New York. Due to its unparalleled ... International clientele. Many patients travel to New York to get their non-surgical skin ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical ... PRO this week. Zeltiq Aesthetics released this new applicator in the United States ... for treating the outer thighs. The original applicator required a 2 hour treatment ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a leading ... venous reflux disease, today,announced the appointment of Peter Osborne ... Administration., Mr. Osborne joins VNUS with over 25 ... Osborne had served as the Company,s,Interim CFO since October ...
... 3 times weekly may increase risk, study suggests , , ... a Mediterranean diet rich in fish, fresh fruits and vegetables, ... their children against asthma and allergies, new research suggests. , ... included 468 mother and child pairs that were followed from ...
... Matters of the mind can affect matters of the heart. ... researchers has found that major anxiety and/or depression, can double ... This is one of the first studies to focus on ... were hospitalized for events such as a heart attack. , ...
... be saved , , FRIDAY, Jan. 18 (HealthDay News) -- If ... die from sudden cardiac arrest could be dramatically reduced. , ... calling for renewed efforts to teach CPR and to find ... the lifesaving technique. , "There is a tremendous opportunity for ...
... Jan. 18 LifeSync Corporation is,pleased to announce ... of Operations. Ms. McLane comes to LifeSync Corporation ... Johnson Company, where she,most recently held the position ... joining Cordis, Ms. McLane spent over 13,years at ...
... brain tumors, dual implantation of radioactive seeds and ... a study led by specialists at the Neuroscience ... University Hospital. , The study, published in the ... that patients treated with simultaneous implantation of radioactive ...
Cached Medicine News:Health News:VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer 2Health News:Mediterranean Diet for Mom Fends Off Asthma, Allergies in Kids 2Health News:Depression and anxiety can double chances of heart ailments 2Health News:Heart Association Renews Call for CPR Training 2Health News:Heart Association Renews Call for CPR Training 3Health News:LifeSync Corporation Appoints Nancy McLane as Senior Vice President Operations 2Health News:Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors 2
... Physiological lesion assessment using Fractional ... proven and cost effective solution ... location of stenosis). Radi's new ... offer fast, easy and accurate ...
... the perfect partner for growing your business ... scalable to meet your needs now and ... your Allura Xper FD20 system supports mixed-use ... to new technologies allows you to add ...
... not slices, changes the way anatomy is ... LightSpeed VCT Series of scanners combine superior ... of difficult patients or procedures more routine., ... the door to new procedures while improving ...
... designed to maximize patient comfort and deliver ... ever to feature Vacuum Pump Deflation Technology. ... reduces the "slamming" effect commonly associated with ... maintains patients comfort and security while treatment ...
Medicine Products: